Pages that link to "Q45963204"
Jump to navigation
Jump to search
The following pages link to Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. (Q45963204):
Displaying 50 items.
- Neurotoxins: Free Radical Mechanisms and Melatonin Protection (Q22305781) (← links)
- Novel therapeutics for Alzheimer's disease: an update (Q24620383) (← links)
- International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors (Q24623433) (← links)
- Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease (Q27024779) (← links)
- Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities (Q27338799) (← links)
- Recent Advances in Neurogenic Small Molecules as Innovative Treatments for Neurodegenerative Diseases (Q28069509) (← links)
- Phenolic Melatonin-Related Compounds: Their Role as Chemical Protectors against Oxidative Stress (Q28073105) (← links)
- Electromagnetic treatment to old Alzheimer's mice reverses β-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit (Q28730323) (← links)
- RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. (Q31134674) (← links)
- Potential future neuroprotective therapies for neurodegenerative disorders and stroke (Q33687436) (← links)
- ASMT gene expression correlates with cognitive impairment in patients with recurrent depressive disorder (Q33738683) (← links)
- Central depressant and nootropic effects of daytime melatonin in mice (Q34153873) (← links)
- A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease (Q34343403) (← links)
- Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders (Q34358480) (← links)
- Significance of high levels of endogenous melatonin in Mammalian cerebrospinal fluid and in the central nervous system (Q34402151) (← links)
- Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease (Q34402167) (← links)
- Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value (Q34416921) (← links)
- Reactive oxygen species in the regulation of synaptic plasticity and memory (Q34805998) (← links)
- Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease (Q34994270) (← links)
- Melatonin in mitochondrial dysfunction and related disorders (Q35001051) (← links)
- N-acetylcysteine prevents spatial memory impairment induced by chronic early postnatal glutaric acid and lipopolysaccharide in rat pups. (Q35036335) (← links)
- Frontiers in Alzheimer's disease therapeutics (Q35086876) (← links)
- Neuronal and vascular oxidative stress in Alzheimer's disease (Q35687039) (← links)
- Sleep disturbances in Alzheimer's and Parkinson's diseases (Q35981780) (← links)
- Melatonin Therapy in Patients with Alzheimer's Disease (Q36335048) (← links)
- Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice (Q36433222) (← links)
- Therapeutic applications of melatonin (Q36671329) (← links)
- Gene and protein patterns of potential prion-related markers in the central nervous system of clinical and preclinical infected sheep (Q36716041) (← links)
- Reduction of Endogenous Melatonin Accelerates Cognitive Decline in Mice in a Simulated Occupational Formaldehyde Exposure Environment (Q36732257) (← links)
- Melatonin: buffering the immune system (Q36820644) (← links)
- Melatonin and abeta, macular degeneration and alzheimers disease: same disease, different outcomes? (Q37612356) (← links)
- An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders (Q37733587) (← links)
- Oxidant/Antioxidant imbalance and the risk of Alzheimer's disease (Q37741560) (← links)
- Melatonin: a multitasking molecule (Q37755679) (← links)
- Matrix metalloproteinases in health and disease: regulation by melatonin (Q37801972) (← links)
- Melatonin has membrane receptor-independent hypnotic action on neurons: an hypothesis (Q37826442) (← links)
- The Role of Mitochondria in Brain Aging and the Effects of Melatonin (Q37848076) (← links)
- Targeting Glycogen Synthase Kinase-3β for Therapeutic Benefit against Oxidative Stress in Alzheimer's Disease: Involvement of the Nrf2-ARE Pathway. (Q37883102) (← links)
- Mitochondrial DNA and inflammatory diseases. (Q37898562) (← links)
- Melatonin as a natural ally against oxidative stress: a physicochemical examination. (Q37900675) (← links)
- Roles of AMP-activated protein kinase in Alzheimer's disease. (Q37988399) (← links)
- Melatonin and mitochondrial dysfunction in the central nervous system (Q37990675) (← links)
- Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. (Q37999105) (← links)
- Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects (Q38004964) (← links)
- Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes (Q38022179) (← links)
- Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity (Q38465387) (← links)
- Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. (Q38476020) (← links)
- Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases. (Q38834700) (← links)
- Update on melatonin receptors: IUPHAR Review 20. (Q38868297) (← links)
- Mechanisms of Melatonin in Alleviating Alzheimer's Disease (Q39178920) (← links)